| Exclusive Interview: Dr. William A. Carter, CEO. Hemispherx Biopharma, Inc. (AMEX:HEB) | | Print | |
| Written by M.E.Garza | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Friday, 12 June 2009 17:48 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Warning: Due To Heavy Traffic And Length, The Screen May Not Load For A Few Seconds. Please Be Patient.
TRT: Approximately 45 Minutes BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section Add this page to your favorite Social Bookmarking websites           
Set as favorite
Bookmark
Email this
Trackback(0)
Comments (26)
M.E.Garza
said:
|
Dr.William A. Carter, the CEO of Hemispherx Biopharma shares his thoughts on the FDA delay, the flu pandemic and the future of his company. Late in the interview he also answers questions submitted to us by our readers. Certainly, the interview is filled with candid revelations and interesting nuggets of new information.
TrackBack URI for this entry
Subscribe to this comment's feed|
... Thanks to everyone who sent in questions earlier in the day and many thanks to everyone who came back after the server was rendered lifeless. Crashed hard by so many thousands who showed up at 8 EST to listen. |
|
Bobbie Gibson
said:
|
... I'm impressed..finally some intelligent conversation ..thank you for the great questions..I've been saying for several days that the delay has alot to do with the appointment of the new commissioner and Dr Carter just stated that. The senate just confirmed Dr Hamburg on 05/18, one week before the original decision date of 05/25..Lots of changes are going on with the FDA thru no fault of HEB's...I'm buying more on Monday !! |
|
Ace Spader
said:
|
... Great interview M.E.Garza. This is a very comprehensive answer from Dr. Carter. It has only strengthened my resolve that Ampligen will get FDA approval soon. |
|
ernest elliott
said:
|
... Awesome interview! Surely all the hebbers will hold tight for the FDA approval! Will it be posted up on Google Monday? |
|
M.E.Garza
said:
|
... You are all very welcome. I'm not sure if it will be posted on Google (next to the price ticker on googlefinance). Many of our stories are (see SPPI), but it seems like someone at google has been editing many of the positive news items for HEB. I know that sounds crazy, but I've gotten many emails and seen postings across the net about this. |
|
Valjack
said:
|
... I wish you could do a real investigation job and find those "japan sources" to obtain interview from THEM - or at least original japanese publication from a different source than HEB - Carter in fact can say everything, investigation (your job) should confirm this FROM OTHER SOURCES please !! |
|
Rick
said:
|
... Great interview....A clear approval and within days. Only a mere delay with FDA due to internal reasons. |
|
7
said:
|
... Thank you M.E.Garza, you never seize to amaze me. I will add a link to your video on our sites. -007 www.mymarketspy.blogspot.com |
|
Thomas oommen
said:
|
... Only one thing to add good Job Dr.Cartor,God bless you.Guys iam going to buy more------------------ |
|
ricardo rodriguez
said:
|
... i have sent several emails to adam feuerstein at the street.com, regarding spreading lies about heb, the articles published in japan need translation, but you can find them if you search for biken i am a share holder of heb and my position has always been long hold, i am sending a link to this video to feuerstein ,we will see if he can lie about this one |
|
Joseph Alexander
said:
|
... Thank you Garza for the great interview. Biomedreports.com has become an excellent resource. Keep doing great reporting. |
|
Hebholder
said:
|
... what a gigantic short interest, heb will skyrocket to 20 like dndn (and this was only good data and not approval) if fda approval on monday. this number has increased up to 10 mln to date in my opinion. so thats why there is alot of negative press around there. remember af was the guy to give dndn a price tag of 1 dollar before the news that dndn endpoints were met. Shares Short (as of 26-May-09)3:7.05M |
|
Her Lao
said:
|
... Thank you, ME Garza, for chosing my single question as one of the 3-4 you put to Dr. Carter. While I knew full well no body --- not Dr. Carter, not us, or any one else --- can do any thing about the FDA's delay, about FDA delays in general, I wanted to gauge Dr. Carter and HEB's reactions to the delay, especially one that, according to HEB was in explicit disregard for the FDA's own institutional reputation. Again, I knew Dr. Carter would be no more privy to the FDA's mysterious working nature as we are... And, yet, to me these instances show why the new FDA chief/commissioner, Dr. Hamburg, initiated a committee to explore ways WITH the FDA, so as to enble the agency to be more TRANSPARENT in its activities, so that it won't be this mysterious, where they can tell us definite time-lines "between 1 to 2 weeks" and totally disregarded them, pretending the time-lines, or deadlines, or appointments, were NEITHER given NOR important... To me, this kind of disregard for one's own timeline in decision-making activities that affect millions in many ways... it is not to be tolerated. As I noted in my question which you put to Dr. Carter, we do NOT expect an aswer/decision we want. But we should expect common courtesy from agencies working on our behalf. If they're going to delay meetings or decisions FURTHER, it is common courtesy to tell the public why. And I just found out, through a case with Savient Pharmaceuticals KRYSTEXXA drug, that the FDA DOES SPEAK TO THE PUBLIC on drugs UNDER REVIEW! The FDA Friday, 6/12, came out to the public to announce, more or less, that they had a difficult time with KRYSTEXXA. The agency's doctors/decision makers SEEM to think the data show promises, good enough to pass, but yet it is still not comfortable enough, so chances are, the agency said, it will convene a panel of experts from OUTSIDE of the agency to gauge their professional expertiese, before making any decision --- whether in the drug's approval, rejection, or in asking for further data... That, to me, is VERY PUBLIC! So, again, we know the FDA DOES TALK about drugs under its review. This nonsense --- every time we call the agency --- about "we don't talk about drugs under review" is BS, now we know unequivocally. To me, this is very valuable information. Again, I hope the new commisioner, Dr. Hamburg, do something to make this agency more user-friendly, more responsive to its customers, US, and acts and behaves more professionally, taking/treating the public, private and public insitutions, and other entities with more regard and common courtesy... Again, thank you, ME Garza, Her Lao This e-mail address is being protected from spambots. You need JavaScript enabled to view it This e-mail address is being protected from spambots. You need JavaScript enabled to view it This e-mail address is being protected from spambots. You need JavaScript enabled to view it |
|
JimmyZ
said:
|
... re "google has been editing many of the positive news items for HEB" That is true. Saw one from StocksHaven via PR-inside on Friday display for 5 mins then Google removed it. Funny how negative ones from TheStreet dont get pulled though. Fcuk google. |
|
hateadam
said:
|
... LIKE THE GOOD NEWS!!! THANK YOU DR.CARTER & MR. GARZA & MRS. WILL DO ALL OF YOU THINK THIS STOCK WILL HIT $20.00? I BELIEVE IT MIGHT BE MORE!!! W.S. |
|
kel
said:
|
... Thanks for doing the interview. The main feed is not playing & the alternate feed cuts off about half way through the interview. |
|
PeterStock
said:
|
... It was great to have such interview. However, Dr. Carter had not really provided any critical information regarding the FDA delay situation. Is he going to just wait indefinitely? Even though he may not able to get any definite answer from FDA, I will still want to know that he has aggressively contacted FDA about the delay instead of sidetracked to other potential opportunties which are not helping to calm down the immediate concern of investors. If the interview has actually provided any critical info or planned action about the the delay situation, please correct me. |
|
Write comment
Sign Up For Phone Alerts
